Sees FY26 Adjusted EBITDA of $18M-$20M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Should l Buy MRVI?
Sees FY26 adjusted EBITDA $18M-$20M.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MRVI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MRVI
Wall Street analysts forecast MRVI stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 3.560
Low
4.50
Averages
4.50
High
4.50
Current: 3.560
Low
4.50
Averages
4.50
High
4.50
About MRVI
Maravai LifeSciences Holdings, Inc. is a life sciences company providing critical products to enable the development of drug therapies, diagnostics and novel vaccines and to support research on human diseases. Its segments include Nucleic Acid Production Segment and Biologics Safety Testing Segment. The Nucleic Acid Production segment is focused on the manufacturing and sale of highly modified nucleic acids products to support the needs of customers’ research, therapeutic and vaccine programs. This segment’s business units include TriLink Discovery, TriLink GMP, Glen Research and Alphazyme. The Biologics Safety Testing segment is focused on manufacturing and selling biologics safety and impurity tests and assay development services that are utilized by its customers in their biologic drug manufacturing activities. This segment’s business is comprised of Cygnus Technologies. It serves various companies, including biopharmaceutical, vaccine, diagnostics and cell and gene therapy.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Maravai LifeSciences Q4 2025 Earnings Call Highlights
- Revenue Beat: Maravai reported full-year revenue of $185.7 million for 2025, exceeding guidance by $700,000, with Q4 revenue at $49.9 million reflecting an 18% year-over-year growth, indicating strong performance under the new operating model.
- Adjusted EBITDA Return: The company achieved positive adjusted EBITDA of over $500,000 in Q4, marking its first return to positive territory in four quarters and an $11 million sequential improvement from Q3, showcasing the effectiveness of cost restructuring.
- Growth Outlook: Maravai expects total revenue of $200 million to $210 million in 2026, representing an 8% to 13% growth over 2025, with adjusted EBITDA projected to reach $18 million to $20 million, reflecting strong confidence in future performance.
- Cost Control Measures: The company anticipates a 13% decline in total operating expenses, with G&A and sales & marketing expenses expected to decrease by 18% and 13% respectively, which will further enhance profitability and competitive positioning.
See More
Maravai LifeSciences Q4 Earnings Report Analysis
- Disappointing Earnings: Maravai LifeSciences reported a Q4 GAAP EPS of -$0.24, missing expectations by $0.13, indicating ongoing profitability challenges that could negatively impact investor confidence.
- Annual Revenue Decline: For the year ended December 31, 2025, total revenue was $185.7 million, reflecting a 28.3% decrease year-over-year, primarily due to a lack of high-volume CleanCap orders, which suggests insufficient market demand for vaccine programs and potential future growth constraints.
- Significant Drop in TriLink Revenue: TriLink's revenue was $119.8 million, down 39.0% year-over-year, driven by the absence of high-volume CleanCap orders, highlighting challenges in a key product line that may lead to further market share erosion.
- Modest Growth in Cygnus Revenue: Cygnus revenue reached $66.0 million, up 5.0% year-over-year, primarily due to strong demand for HCP kits and qualification services, indicating some business stability despite overall poor performance.
See More
Maravai LifeSciences to Announce Q4 Earnings on February 25
- Earnings Announcement Schedule: Maravai LifeSciences Holdings (MRVI) is set to release its Q4 earnings report on February 25 after market close, with consensus EPS estimate at -$0.07 and revenue estimate at $49.06 million.
- Historical Performance Review: Over the past two years, MRVI has only beaten EPS estimates 13% of the time, while it has exceeded revenue estimates 50% of the time, indicating uncertainty in the company's earnings forecasts.
- Market Reaction Expectations: Given the company's historical underperformance against EPS and revenue estimates, investors may approach the upcoming earnings report with caution, potentially impacting stock price volatility.
- Analyst Rating Insights: Seeking Alpha's Quant Rating on Maravai LifeSciences Holdings will provide investors with further market insights, aiding in the assessment of the company's future financial performance and investment value.
See More
Maravai to Announce Q4 and Full Year 2025 Financial Results
- Earnings Announcement Schedule: Maravai LifeSciences plans to release its Q4 and full year 2025 financial and operational results after market close on February 25, 2026, reflecting the company's commitment to transparency and investor communication.
- Conference Call Details: The company will host a conference call on the same day at 2:00 PM PT/5:00 PM ET, allowing investors to dial in at 1-800-343-4136 or 1-203-518-9843, enhancing engagement with stakeholders.
- Webcast Availability: The conference call will be available via live or archived webcast on the
See More
Maravai to Announce Q4 and Full Year 2025 Results
- Earnings Announcement Schedule: Maravai LifeSciences plans to release its Q4 and full year 2025 financial and operational results after market close on February 25, 2026, reflecting the company's commitment to transparency and investor communication.
- Conference Call Details: The company will host a conference call on the same day at 2:00 PM PT/5:00 PM ET, allowing investors to dial in at 1-800-343-4136 or 1-203-518-9843 to access critical information promptly.
- Webcast Availability: The conference call will also be available via live or archived webcast on the
See More
Aptamer Licenses Optimer for Hot-Start PCR to Alphazyme, Securing Global Rights
- Licensing Agreement: Aptamer Group has entered into a licensing agreement with Alphazyme, a Maravai LifeSciences company, granting the latter a non-exclusive license to use an enzyme-modulating Optimer in hot-start PCR and next-generation sequencing applications, marking a strategic collaboration in the biotech sector.
- Global Rights Granted: The agreement provides Alphazyme with worldwide rights, including royalty payments on product sales and milestone payments, which are expected to generate a continuous revenue stream for Aptamer.
- Manufacturing Collaboration: Aptamer will manufacture the Optimer for Alphazyme, ensuring product quality control while enhancing Aptamer's manufacturing capabilities and competitive position in the biopharmaceutical industry.
- Positive Stock Reaction: Following the announcement of the agreement, Aptamer's shares rose by 4% to GBp 0.8378 on the London Stock Exchange, reflecting market optimism regarding the prospects of this collaboration.
See More
Maravai LifeSciences Q4 2025 Earnings Call Highlights
- Revenue Beat: Maravai reported full-year revenue of $185.7 million for 2025, exceeding guidance by $700,000, with Q4 revenue at $49.9 million reflecting an 18% year-over-year growth, indicating strong performance under the new operating model.
- Adjusted EBITDA Return: The company achieved positive adjusted EBITDA of over $500,000 in Q4, marking its first return to positive territory in four quarters and an $11 million sequential improvement from Q3, showcasing the effectiveness of cost restructuring.
- Growth Outlook: Maravai expects total revenue of $200 million to $210 million in 2026, representing an 8% to 13% growth over 2025, with adjusted EBITDA projected to reach $18 million to $20 million, reflecting strong confidence in future performance.
- Cost Control Measures: The company anticipates a 13% decline in total operating expenses, with G&A and sales & marketing expenses expected to decrease by 18% and 13% respectively, which will further enhance profitability and competitive positioning.
See More
Maravai LifeSciences Q4 Earnings Report Analysis
- Disappointing Earnings: Maravai LifeSciences reported a Q4 GAAP EPS of -$0.24, missing expectations by $0.13, indicating ongoing profitability challenges that could negatively impact investor confidence.
- Annual Revenue Decline: For the year ended December 31, 2025, total revenue was $185.7 million, reflecting a 28.3% decrease year-over-year, primarily due to a lack of high-volume CleanCap orders, which suggests insufficient market demand for vaccine programs and potential future growth constraints.
- Significant Drop in TriLink Revenue: TriLink's revenue was $119.8 million, down 39.0% year-over-year, driven by the absence of high-volume CleanCap orders, highlighting challenges in a key product line that may lead to further market share erosion.
- Modest Growth in Cygnus Revenue: Cygnus revenue reached $66.0 million, up 5.0% year-over-year, primarily due to strong demand for HCP kits and qualification services, indicating some business stability despite overall poor performance.
See More
Maravai LifeSciences to Announce Q4 Earnings on February 25
- Earnings Announcement Schedule: Maravai LifeSciences Holdings (MRVI) is set to release its Q4 earnings report on February 25 after market close, with consensus EPS estimate at -$0.07 and revenue estimate at $49.06 million.
- Historical Performance Review: Over the past two years, MRVI has only beaten EPS estimates 13% of the time, while it has exceeded revenue estimates 50% of the time, indicating uncertainty in the company's earnings forecasts.
- Market Reaction Expectations: Given the company's historical underperformance against EPS and revenue estimates, investors may approach the upcoming earnings report with caution, potentially impacting stock price volatility.
- Analyst Rating Insights: Seeking Alpha's Quant Rating on Maravai LifeSciences Holdings will provide investors with further market insights, aiding in the assessment of the company's future financial performance and investment value.
See More
Maravai to Announce Q4 and Full Year 2025 Financial Results
- Earnings Announcement Schedule: Maravai LifeSciences plans to release its Q4 and full year 2025 financial and operational results after market close on February 25, 2026, reflecting the company's commitment to transparency and investor communication.
- Conference Call Details: The company will host a conference call on the same day at 2:00 PM PT/5:00 PM ET, allowing investors to dial in at 1-800-343-4136 or 1-203-518-9843, enhancing engagement with stakeholders.
- Webcast Availability: The conference call will be available via live or archived webcast on the
See More
Maravai to Announce Q4 and Full Year 2025 Results
- Earnings Announcement Schedule: Maravai LifeSciences plans to release its Q4 and full year 2025 financial and operational results after market close on February 25, 2026, reflecting the company's commitment to transparency and investor communication.
- Conference Call Details: The company will host a conference call on the same day at 2:00 PM PT/5:00 PM ET, allowing investors to dial in at 1-800-343-4136 or 1-203-518-9843 to access critical information promptly.
- Webcast Availability: The conference call will also be available via live or archived webcast on the
See More
Aptamer Licenses Optimer for Hot-Start PCR to Alphazyme, Securing Global Rights
- Licensing Agreement: Aptamer Group has entered into a licensing agreement with Alphazyme, a Maravai LifeSciences company, granting the latter a non-exclusive license to use an enzyme-modulating Optimer in hot-start PCR and next-generation sequencing applications, marking a strategic collaboration in the biotech sector.
- Global Rights Granted: The agreement provides Alphazyme with worldwide rights, including royalty payments on product sales and milestone payments, which are expected to generate a continuous revenue stream for Aptamer.
- Manufacturing Collaboration: Aptamer will manufacture the Optimer for Alphazyme, ensuring product quality control while enhancing Aptamer's manufacturing capabilities and competitive position in the biopharmaceutical industry.
- Positive Stock Reaction: Following the announcement of the agreement, Aptamer's shares rose by 4% to GBp 0.8378 on the London Stock Exchange, reflecting market optimism regarding the prospects of this collaboration.
See More
